局限期小细胞肺癌每日一次或两次放疗及年龄影响的真实世界数据
年轻患者(<70岁)接受每日两次放疗的总生存显著更长,且急性毒性未增加;≥70岁患者两种方案总生存无差异。
要点
- 年轻患者每日两次放疗总生存显著优于每日一次,急性毒性未增加。
- ≥70岁患者每日两次与每日一次放疗总生存无差异。
- ≥70岁患者每日两次放疗急性毒性数值上更高但差异无统计学意义。
核心结论
- 年轻局限期小细胞肺癌患者每日两次放疗较每日一次总生存显著延长,且未增加90天急性毒性。
- 70岁及以上患者两种放疗方案的总生存无差异。
研究设计与样本
- 平均年龄66.7岁(SD 8.5),59.8%患者<70岁;比较每日一次与每日两次放疗的90天急性毒性和总生存。
- 生存采用多变量Cox模型评估,急性毒性采用多变量逻辑回归模型评估。
主要发现
- ≥70岁患者中80.4%接受每日两次放疗,总生存与每日一次无差异(21.8 vs 24.3个月;调整HR 1.3;95%CI 0.76-2.28)。
- <70岁患者每日两次与每日一次急性毒性无差异(26.0% vs 30.2%;OR 0.85;95%CI 0.41-1.84)。
- ≥70岁患者每日两次较每日一次急性毒性数值上更高(28.1% vs 19.5%;OR 1.43;95%CI 0.57-3.77)。
临床怎么用
- 对<70岁局限期小细胞肺癌患者,可优先考虑每日两次胸部放疗以改善总生存。
- 对≥70岁患者,每日两次与每日一次放疗的总生存无差异,需结合个体情况选择方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We aimed to assess acute toxicity and overall survival (OS) in patients with limited-stage small-cell lung cancer (LS-SCLC) who received concurrent thoracic chemoradiotherapy using either once-daily (OD) or twice-daily (BID) radiation therapy and compare these outcomes in 2 age groups. METHODS AND MATERIALS: Data from the Dutch Lung Cancer Audit-Radiation therapy were prospectively recorded. Acute 90-day toxicity and OS in patients treated with OD and BID radiotherapy were compared in patients younger and older than 70 years. Survival was assessed in a multivariable Cox model. Acute toxicity was assessed in a multivariable logistic regression model. RESULTS: Seven hundred eleven patients with LS-SCLC starting treatment between 2016 and 2023 were included. Mean age was 66.7 years (SD 8.5). In total, 59.8% of patients were younger than 70 years, of whom 85.2% were treated with a BID regimen. In younger patients treated BID, median OS was significantly longer (36.0 vs 22.2 months, adjusted hazard ratio, 0.61; 95% CI, 0.41-0.89, P = .01). In patients ≥70 years, 80.4% were treated BID. There was no difference in OS (21.8 vs 24.3 months; adjusted hazard ratio, 1.3; 95% CI, 0.76-2.28). No difference in acute toxicity was observed in younger patients treated BID (26.0%) versus OD (30.2%) (OR, 0.85; 95% CI, 0.41-1.84). Older patients treated BID had numerically higher toxicity (28.1%) compared with patients treated OD (19.5%) (OR 1.43; 95% CI, 0.57-3.77). CONCLUSIONS: A significantly longer OS in younger patients with LS-SCLC treated with BID radiotherapy compared with OD was observed, without increase in acute 90-day toxicity. No difference in OS between regimens in patients 70 years or older was found.
引用
- Bosch FTM, Damhuis R, Peters M, et al. Real-World Data on Once or Twice-Daily Radiation Therapy and the Effect of Age in Patients With Limited-Stage Small-Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2026. PMID: 42556587. doi:10.1016/j.ijrobp.2026.07.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。